PANTHERx® Rare Pharmacy Once Again Earns Top Ranking in Quarterly MMIT Patient Satisfaction Survey
December 7, 2023 PITTSBURGH – PANTHERx Rare, the six-time winner of the Annual MMIT Patient Choice Award, once again, has...
Read More
PANTHERx® Selected by UCB as part of the Limited Specialty Pharmacy Network for RYSTIGGO® (rozanolixizumab-noli), for the Treatment of Generalized Myasthenia Gravis (gMG)
August 2, 2023 PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United...
Read More
PANTHERx® Rare Announces Exciting Leadership Changes: New President and Key Hire
June 20, 2023 PITTSBURGH – PANTHERx® Rare, the nation’s leading rare disease pharmacy, is excited to announce significant...
Read More
PANTHERx® Rare Pharmacy Expands Services to Include Dispensing AYVAKIT® (avapritinib) for the Expanded Approval for Treatment of Indolent Systemic Mastocytosis (ISM)
June 19, 2023 PITTSBURGH – Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded...
Read More
PANTHERx® Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT® (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam
June 27, 2022 PITTSBURGH – PANTHERx® Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy...
Read More
PANTHERx Rare Celebrates Fifth Patient Choice Award Win
May 4, 2022 PITTSBURGH – For a fifth time, PANTHERx® Rare has been recognized as the winner of the annual, Specialty Pharmacy...
Read More
